ArticleGeroScience2025
Epigenetic dysregulation of transposable elements in cognitive impairment and Alzheimer's disease.
Article in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Distinct Transposable Element Transcript Patterns in Microglia Across Aging and Alzheimer's Disease.Aging cell · 2026Article
- Differential gene expression of retrotransposons (LTR and non-LTR) in peripheral blood leukocytes of people with gout.Arthritis research & therapy · 2026Article
- Longitudinal Repeatome Remodeling in Peripheral Blood Following Parkinson's Disease Diagnosis.Genes · 2026Article
- Integrated epigenetic networks in aging: from histone to RNA modifications.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Aging and cognitive impairment increase the risk for Alzheimer's disease (AD), and growing evidence suggests that transposable elements (TEs) in the genome play a role in aging and AD. The mechanisms of TE dysregulation in this context are unclear, but one possibility is that epigenetic changes, including DNA hypomethylation and/or reduced chromatin structure, underlie age- and AD-related TE activity. Therefore, the purpose of the present study was to generate a resource for studying TE epigenetics in aging and AD, and to use it to determine if epigenetically dysregulated TEs are related to age/AD-relevant clinical outcomes. We performed RNA-seq on peripheral blood samples from 45 healthy older adults, mild cognitive impairment (MCI) and AD dementia patients, and we observed a pattern of undulating TE transcript expression with MCI and AD, similar to previous reports. We then used whole-genome bisulfite sequencing (WGBS) and transposase-accessible chromatin sequencing (ATAC-seq) to characterize global DNA methylation and chromatin accessibility in the same subjects. We found that most TEs that were enriched/dysregulated in our RNA-seq data with MCI and AD could be found within hypomethylated and chromatin-accessible regions of the genome. These TEs included several that have been directly linked to inflammation and disease in humans, and they were related to cognitive/functional diagnosis, age, and biomarkers of inflammation and neurodegeneration in the subjects we studied. Collectively, these findings are consistent with the idea that epigenetic alterations may contribute to TE transcript dysregulation that plays an important role in aging, cognitive decline, and AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.